Divi's Laboratories said its unit at Choutuppal in Telangana has undergone successful inspection by the US health regulator with no observations.  The company's unit-I at Choutuppal has had an inspection by the United States Food and Drug Administration (USFDA) from May 14-16, 2018. "This was a general cGMP inspection by USFDA. The inspection has been concluded with no 483 observations," it added in a BSE filing. As per USFDA, form 483 observations are issued after conclusion of inspection to notify the company's management of objectionable conditions at its facility. – Business Standard

10 Diagnostic Imaging Trends for 2018



Digital version